Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of…
Eisai Co., Ltd. and Seikagaku Corporation announced that the companies have entered into an agreement for the marketing alliance in South Korea for SI-613 (diclofenac conjugated sodium…
Read More...
Read More...
